S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin

Table 1 Distribution of S100A10 status in ovarian cancer according to clinicopathological characteristics

Clinical Variable	Patients	S100A10 expression (No. of cases)		P Value
Clinical Variable	Patients	Low	High	P Value
All cases	138	65	73
Age at Diagnosis	≥60	24	16	0.013
Age at Diagnosis	< 60	45	53	0.013
Residual tumor size (cm)	≥2	19	16	0.557
Residual tumor size (cm)	< 2	50	53	0.557
Level of CA125 in primary tumors (U/ml)	≥500	50	55	0.318
Level of CA125 in primary tumors (U/ml)	< 500	19	14	0.318
Recurrent type	Carboplatin-sensitive	49	26	< 0.001
Recurrent type	Carboplatin-resistant	20	43	< 0.001
FIGO stage	III	57	52	0.296
FIGO stage	IV	12	17	0.296
Tumor grade	G1/G2	29	18	0.048
Tumor grade	G3	40	51	0.048